Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus.
Alphapapillomavirus
Early Detection of Cancer
Female
HIV
HIV Infections
/ diagnosis
Human papillomavirus 16
/ genetics
Human papillomavirus 18
Humans
Mass Screening
Middle Aged
Papillomaviridae
/ genetics
Papillomavirus Infections
/ diagnosis
Pregnancy
Uterine Cervical Neoplasms
/ diagnosis
Vaginal Smears
Uterine Cervical Dysplasia
HIV
cervical cancer screening
human papillomavirus (HPV)
p16/Ki-67
primary HPV screening
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
04 05 2021
04 05 2021
Historique:
received:
12
02
2020
pubmed:
4
9
2020
medline:
21
5
2021
entrez:
4
9
2020
Statut:
ppublish
Résumé
Primary human papillomavirus (HPV) screening (PHS) utilizes oncogenic human papillomavirus (oncHPV) testing as the initial cervical cancer screening method and typically, if positive, additional reflex-triage (eg, HPV16/18-genotyping, Pap testing). While US guidelines support PHS usage in the general population, PHS has been little studied in women living with HIV (WLWH). We enrolled n = 865 WLWH (323 from the Women's Interagency HIV Study [WIHS] and 542 from WIHS-affiliated colposcopy clinics). All participants underwent Pap and oncHPV testing, including HPV16/18-genotyping. WIHS WLWH who tested oncHPV[+] or had cytologic atypical squamous cells of undetermined significance or worse (ASC-US+) underwent colposcopy, as did a random 21% of WLWH who were oncHPV[-]/Pap[-] (controls). Most participants additionally underwent p16/Ki-67 immunocytochemistry. Mean age was 46 years, median CD4 was 592 cells/µL, 95% used antiretroviral therapy. Seventy WLWH had histologically-determined cervical intraepithelial neoplasia grade 2 or greater (CIN-2+), of which 33 were defined as precancer (ie, [i] CIN-3+ or [ii] CIN-2 if concurrent with cytologic high grade squamous intraepithelial lesions [HSILs]). PHS had 87% sensitivity (Se) for precancer, 9% positive predictive value (PPV), and a 35% colposcopy referral rate (Colpo). "PHS with reflex HPV16/18-genotyping and Pap testing" had 84% Se, 16% PPV, 30% Colpo. PHS with only HPV16/18-genotyping had 24% Colpo. "Concurrent oncHPV and Pap Testing" (Co-Testing) had 91% Se, 12% PPV, 40% Colpo. p16/Ki-67 immunochemistry had the highest PPV, 20%, but 13% specimen inadequacy. PHS with reflex HPV16/18-genotyping had fewer unnecessary colposcopies and (if confirmed) could be a potential alternative to Co-Testing in WLWH.
Sections du résumé
BACKGROUND
Primary human papillomavirus (HPV) screening (PHS) utilizes oncogenic human papillomavirus (oncHPV) testing as the initial cervical cancer screening method and typically, if positive, additional reflex-triage (eg, HPV16/18-genotyping, Pap testing). While US guidelines support PHS usage in the general population, PHS has been little studied in women living with HIV (WLWH).
METHODS
We enrolled n = 865 WLWH (323 from the Women's Interagency HIV Study [WIHS] and 542 from WIHS-affiliated colposcopy clinics). All participants underwent Pap and oncHPV testing, including HPV16/18-genotyping. WIHS WLWH who tested oncHPV[+] or had cytologic atypical squamous cells of undetermined significance or worse (ASC-US+) underwent colposcopy, as did a random 21% of WLWH who were oncHPV[-]/Pap[-] (controls). Most participants additionally underwent p16/Ki-67 immunocytochemistry.
RESULTS
Mean age was 46 years, median CD4 was 592 cells/µL, 95% used antiretroviral therapy. Seventy WLWH had histologically-determined cervical intraepithelial neoplasia grade 2 or greater (CIN-2+), of which 33 were defined as precancer (ie, [i] CIN-3+ or [ii] CIN-2 if concurrent with cytologic high grade squamous intraepithelial lesions [HSILs]). PHS had 87% sensitivity (Se) for precancer, 9% positive predictive value (PPV), and a 35% colposcopy referral rate (Colpo). "PHS with reflex HPV16/18-genotyping and Pap testing" had 84% Se, 16% PPV, 30% Colpo. PHS with only HPV16/18-genotyping had 24% Colpo. "Concurrent oncHPV and Pap Testing" (Co-Testing) had 91% Se, 12% PPV, 40% Colpo. p16/Ki-67 immunochemistry had the highest PPV, 20%, but 13% specimen inadequacy.
CONCLUSIONS
PHS with reflex HPV16/18-genotyping had fewer unnecessary colposcopies and (if confirmed) could be a potential alternative to Co-Testing in WLWH.
Identifiants
pubmed: 32881999
pii: 5901172
doi: 10.1093/cid/ciaa1317
pmc: PMC8096228
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1529-1537Subventions
Organisme : NCI NIH HHS
ID : R01 CA085178
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD032632
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103401
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103408
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI031834
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103397
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI042590
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034994
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035004
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103390
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034989
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000454
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034993
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA174634
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146202
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA013330
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000004
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
JAMA. 2018 Aug 21;320(7):647-649
pubmed: 30140859
Arch Pathol Lab Med. 2020 Jun;144(6):725-734
pubmed: 31718233
J Low Genit Tract Dis. 2004 Oct;8(4):298-303
pubmed: 15874876
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):405-13
pubmed: 23254153
JAMA. 2012 Jul 25;308(4):362-9
pubmed: 22820789
Am J Obstet Gynecol. 2016 Mar;214(3):354.e1-6
pubmed: 26433170
Epidemiology. 1998 Mar;9(2):117-25
pubmed: 9504278
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
AIDS. 2014 Jul 17;28(11):1696-8
pubmed: 25232904
Int J Epidemiol. 2018 Apr 1;47(2):393-394i
pubmed: 29688497
Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1407-1415
pubmed: 30237251
Int J Cancer. 2016 Mar 15;138(6):1453-61
pubmed: 26421807
J Clin Virol. 2016 Sep;82:145-151
pubmed: 27498250
AIDS. 2018 Nov 28;32(18):2821-2826
pubmed: 30234608
Obstet Gynecol. 2006 Aug;108(2):264-72
pubmed: 16880294
AIDS. 2014 Mar 27;28(6):881-90
pubmed: 24300545
J Low Genit Tract Dis. 2009 Jul;13(3):137-44
pubmed: 19550210
Tumori. 2016 Oct 13;102(5):450-458
pubmed: 27443891
Am J Clin Pathol. 2016 Jan;145(1):35-45
pubmed: 26712869
Virology. 2005 Jun 20;337(1):76-84
pubmed: 15914222
AIDS. 2020 Jan 1;34(1):73-80
pubmed: 31789890
Gynecol Oncol. 2015 Feb;136(2):178-82
pubmed: 25579107
Clin Infect Dis. 2015 Nov 15;61(10):1573-81
pubmed: 26187020
PLoS One. 2017 Oct 12;12(10):e0185597
pubmed: 29023464
Int J Cancer. 2015 Feb 15;136(4):E146-53
pubmed: 25081507
Lancet Oncol. 2011 Sep;12(9):880-90
pubmed: 21865084
CA Cancer J Clin. 2020 Sep;70(5):321-346
pubmed: 32729638
Int J Cancer. 2008 Jul 1;123(1):187-94
pubmed: 18435450
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884